BriaCell Therapeutics Corp. financial data

Symbol
BCTX, BCTXL, BCTXW, BCTXZ on Nasdaq
Location
West Vancouver, British Columbia, Canada
Fiscal year end
31 July
Latest financial report
10-Q - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 528% % 425%
Return On Equity -172% % -107%
Return On Assets -139% % 4.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7,250,487 shares 95%
Common Stock, Shares, Outstanding 7,250,487 shares 2360%
Entity Public Float $94,477,705 USD 48%
Common Stock, Value, Issued $117,117,225 USD 37%
Weighted Average Number of Shares Outstanding, Basic 2,802,337 shares 938%
Weighted Average Number of Shares Outstanding, Diluted 2,802,337 shares 938%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $24,657,892 USD 15%
General and Administrative Expense $6,078,845 USD 2.9%
Operating Income (Loss) $30,736,737 USD -13%
Nonoperating Income (Expense) $278,674 USD 248%
Net Income (Loss) Attributable to Parent $29,637,657 USD -156%
Earnings Per Share, Basic -13.14 USD/shares 85%
Earnings Per Share, Diluted -13.14 USD/shares 85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $29,903,628 USD 496%
Accounts Receivable, after Allowance for Credit Loss, Current $15,233 USD 2.3%
Assets, Current $32,178,884 USD 349%
Property, Plant and Equipment, Net $251,141 USD -27%
Intangible Assets, Net (Excluding Goodwill) $180,707 USD -7.8%
Assets $33,594,454 USD 259%
Liabilities, Current $3,185,550 USD -39%
Accumulated Other Comprehensive Income (Loss), Net of Tax $138,684 USD 0%
Retained Earnings (Accumulated Deficit) $127,174,949 USD -30%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $30,213,808 USD 836%
Liabilities and Equity $33,594,454 USD 259%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,704,796 USD -11%
Net Cash Provided by (Used in) Financing Activities $11,960,252 USD
Net Cash Provided by (Used in) Investing Activities $75,000 USD 0%
Common Stock, Shares, Issued 7,250,487 shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,779,796 USD -258%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $29,903,628 USD 496%
Deferred Tax Assets, Valuation Allowance $24,329,720 USD 35%
Deferred Tax Assets, Gross $28,431,010 USD 30%
Depreciation $22,839 USD 0%
Property, Plant and Equipment, Gross $456,801 USD
Deferred Tax Assets, Operating Loss Carryforwards $8,494,300 USD 53%
Unrecognized Tax Benefits $0 USD
Deferred Tax Assets, Net of Valuation Allowance $4,101,290 USD 4.9%
Share-based Payment Arrangement, Expense $392,215 USD 39%